JP2021516757A5 - - Google Patents
Info
- Publication number
- JP2021516757A5 JP2021516757A5 JP2020543884A JP2020543884A JP2021516757A5 JP 2021516757 A5 JP2021516757 A5 JP 2021516757A5 JP 2020543884 A JP2020543884 A JP 2020543884A JP 2020543884 A JP2020543884 A JP 2020543884A JP 2021516757 A5 JP2021516757 A5 JP 2021516757A5
- Authority
- JP
- Japan
- Prior art keywords
- cd11b
- mhcii
- subject
- level
- disease
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127159A JP2023159164A (ja) | 2018-03-27 | 2023-08-03 | ファーバー病マーカーおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648775P | 2018-03-27 | 2018-03-27 | |
| US62/648,775 | 2018-03-27 | ||
| PCT/IB2019/000290 WO2019186272A1 (en) | 2018-03-27 | 2019-03-22 | Farber disease markers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127159A Division JP2023159164A (ja) | 2018-03-27 | 2023-08-03 | ファーバー病マーカーおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516757A JP2021516757A (ja) | 2021-07-08 |
| JP2021516757A5 true JP2021516757A5 (https=) | 2022-03-28 |
| JPWO2019186272A5 JPWO2019186272A5 (https=) | 2022-03-28 |
Family
ID=66530353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543884A Pending JP2021516757A (ja) | 2018-03-27 | 2019-03-22 | ファーバー病マーカーおよびその使用 |
| JP2023127159A Pending JP2023159164A (ja) | 2018-03-27 | 2023-08-03 | ファーバー病マーカーおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127159A Pending JP2023159164A (ja) | 2018-03-27 | 2023-08-03 | ファーバー病マーカーおよびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3775924A1 (https=) |
| JP (2) | JP2021516757A (https=) |
| KR (2) | KR20200136367A (https=) |
| CN (2) | CN111971562A (https=) |
| AU (1) | AU2019244477A1 (https=) |
| BR (1) | BR112020016435A2 (https=) |
| CA (1) | CA3090354A1 (https=) |
| CL (1) | CL2020002105A1 (https=) |
| CO (1) | CO2020010043A2 (https=) |
| IL (2) | IL311212A (https=) |
| MX (1) | MX2020008377A (https=) |
| PH (1) | PH12020551206A1 (https=) |
| RU (1) | RU2020119065A (https=) |
| SG (1) | SG11202007508TA (https=) |
| WO (1) | WO2019186272A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020152532A1 (en) * | 2019-01-23 | 2020-07-30 | Enzyvant Therapeutics Gmbh | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
| US20240180982A1 (en) * | 2021-03-29 | 2024-06-06 | University College Cardiff Consultants Limited | Modified adenovirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1995001164A1 (en) | 1993-06-30 | 1995-01-12 | Genentech, Inc. | Method for preparing liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| CA2905449C (en) | 2013-03-14 | 2024-09-10 | Icahn School Of Medicine At Mount Sinai | THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE |
| EP3115786A1 (en) * | 2015-07-08 | 2017-01-11 | Centogene AG | Method for the diagnosis of farber's disease |
-
2019
- 2019-03-22 CA CA3090354A patent/CA3090354A1/en active Pending
- 2019-03-22 CN CN201980008575.9A patent/CN111971562A/zh active Pending
- 2019-03-22 JP JP2020543884A patent/JP2021516757A/ja active Pending
- 2019-03-22 RU RU2020119065A patent/RU2020119065A/ru unknown
- 2019-03-22 EP EP19723847.0A patent/EP3775924A1/en not_active Withdrawn
- 2019-03-22 KR KR1020207023065A patent/KR20200136367A/ko not_active Ceased
- 2019-03-22 IL IL311212A patent/IL311212A/en unknown
- 2019-03-22 MX MX2020008377A patent/MX2020008377A/es unknown
- 2019-03-22 CN CN202311688835.6A patent/CN118112249A/zh active Pending
- 2019-03-22 AU AU2019244477A patent/AU2019244477A1/en not_active Abandoned
- 2019-03-22 BR BR112020016435-6A patent/BR112020016435A2/pt unknown
- 2019-03-22 KR KR1020247022597A patent/KR20240111011A/ko not_active Ceased
- 2019-03-22 SG SG11202007508TA patent/SG11202007508TA/en unknown
- 2019-03-22 WO PCT/IB2019/000290 patent/WO2019186272A1/en not_active Ceased
-
2020
- 2020-07-30 IL IL276420A patent/IL276420A/en unknown
- 2020-08-07 PH PH12020551206A patent/PH12020551206A1/en unknown
- 2020-08-14 CO CONC2020/0010043A patent/CO2020010043A2/es unknown
- 2020-08-14 CL CL2020002105A patent/CL2020002105A1/es unknown
-
2023
- 2023-08-03 JP JP2023127159A patent/JP2023159164A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | A strategy of vascular‐targeted therapy for liver fibrosis | |
| Lotz et al. | Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis | |
| Kerr et al. | Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition | |
| Mathé et al. | L-nucleoside enantiomers as antivirals drugs: a mini-review | |
| ES2585702T3 (es) | Composiciones y métodos para la unión al ácido lisofosfatídico | |
| Steineck et al. | Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: A randomized trial | |
| Gemmel et al. | Future diagnostic agents | |
| Di Battista et al. | One year in review 2021: systemic sclerosis | |
| Akagi et al. | Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension | |
| US20200188471A1 (en) | Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis | |
| Shi et al. | Augmenter of liver regeneration protects against carbon tetrachloride-induced liver injury by promoting autophagy in mice | |
| KR20110074898A (ko) | 염증을 치료하는 방법 | |
| JP2006519799A (ja) | Ｉｐ−１０が媒介した疾患の処置又は予防用の、チアゾリジンジオンを有する薬学的調製物 | |
| EA030513B1 (ru) | Комбинированная фармацевтическая композиция и способ лечения и профилактики инфекционных заболеваний | |
| JP2021516757A5 (https=) | ||
| JPH11506737A (ja) | 小細胞肺ガンを治療または検出するためのコノトキシンペプチドｕ００２およびｍｉｉの使用 | |
| RU2020119065A (ru) | Маркеры болезни фарбера и их применения | |
| JP2020073508A (ja) | 多発性骨髄腫治療 | |
| de Freitas et al. | Effects of exercise training and stem cell therapy on the left ventricle of infarcted rats | |
| Scheurer et al. | A case series highlighting the role of different gamma-herpesviruses in Equine Multinodular Pulmonary Fibrosis | |
| Chang et al. | ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAïVE HBEAG (+) PATIENTS (ETV 022/901): 109 | |
| CN114895042A (zh) | S100a11基因或蛋白作为生物标记物在制备诊断、预防或治疗肝纤维化的产品的应用 | |
| JPWO2019186272A5 (https=) | ||
| Nikunjkumar et al. | Ribavirin as a curative and prophylactic agent against foot and mouth disease virus infection in C57BL/6 suckling and adult mice model | |
| CN112638420A (zh) | 治疗银屑病的方法 |